| Literature DB >> 27294126 |
Rizwana Afroz1, E M Tanvir2, Nurul Karim3, Md Sabir Hossain3, Nadia Alam4, Siew Hua Gan4, Md Ibrahim Khalil5.
Abstract
The present study was designed to investigate the cardioprotective effects of Sundarban honey (SH) in rats with isoproterenol- (ISO-) induced myocardial infarction. Adult male Wistar Albino rats were pretreated with Sundarban honey (5 g/kg) daily for a period of 6 weeks. After the treatment period, ISO (85 mg/kg) was subcutaneously injected into the rats at 24 h intervals for 2 days. ISO-induced myocardial damage was indicated by increased serum cardiac specific troponin I levels and cardiac marker enzyme activities including creatine kinase-MB, lactate dehydrogenase, aspartate transaminase, and alanine transaminase. Significant increases in serum total cholesterol, triglycerides, and low-density lipoprotein-cholesterol levels were also observed, along with a reduction in the serum high-density lipoprotein-cholesterol level. In addition to these diagnostic markers, the levels of lipid peroxide products were significantly increased. The activities of antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, and glutathione reductase were significantly decreased in the hearts after ISO-induced myocardial infarction. However, pretreatment of ischemic rats with Sundarban honey brought the biochemical parameters to near normalcy, indicating the protective effect of Sundarban honey against ISO-induced ischemia in rats. Histopathological findings of the heart tissues further confirmed the biochemical findings, indicating that Sundarban honey confers protection against ISO-induced oxidative stress in the myocardium.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27294126 PMCID: PMC4886051 DOI: 10.1155/2016/6437641
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Schematic representation of experimental design of the study.
The effects of SH on the body and heart weights of the rats.
| Parameters | Treatment | Percentage change | |||||
|---|---|---|---|---|---|---|---|
| Sham | SH + sham | SH + ISO | ISO | SH + sham | SH + ISO | ISO | |
| Initial body weight (g) | 183.75 ± 9.09a | 181.22 ± 8.14a | 187.78 ± 4.69a | 178.78 ± 3.50a | −1.38% | 2.19% | −2.70% |
| Final body weight (g) | 219 ± 3.54a | 206.11 ± 5.44a | 220.22 ± 8.39a | 217.83 ± 3.06a | −5.89% | 0.56% | −0.53% |
| Body weight gain (g) | 31.5 ± 6.36a | 24.89 ± 2.89a | 32.67 ± 3.77a | 32.75 ± 3.79a | −20.98% | 3.71% | 3.96% |
| Heart weight (g) | 0.85 ± 0.01a | 0.84 ± 0.01a | 1.07 ± 0.02b | 1.14 ± 0.01c | −1.17% | 25.88% | 34.12% |
Results are expressed as the mean ± SD, n = 8. Values in the same row not sharing a common superscript (a, b, and c) differ significantly with each other at p < 0.05. Percentage change is calculated as 100 × [(value of treatment − value of sham)/value of sham].
Figure 2The effects of SH on serum cTn I levels. The bars represent the mean ± SD (n = 8); bars with different letters are significantly different at p < 0.05.
Figure 3The cardioprotective effects of SH on the activities of cardiac marker enzymes. The bars represent the mean ± SD (n = 8); bars with different letters are significantly different at p < 0.05.
The antihyperlipidemic effects of SH on the serum lipid profiles.
| Parameters | Treatment | Percentage change | |||||
|---|---|---|---|---|---|---|---|
| Sham | SH + sham | SH + ISO | ISO | SH + sham | SH + ISO | ISO | |
| TC (mg/dL) | 53.04 ± 2.34a | 47.54 ± 0.80a | 57.74 ± 3.13a | 72.48 ± 2.41b | −10.37% | 8.86% | 36.65% |
| TGs (mg/dL) | 38.13 ± 2.07ab | 29.38 ± 1.09a | 38.19 ± 3.65ab | 63.04 ± 0.47c | −22.95% | 0.16% | 65.33% |
| LDL-C (mg/dL) | 19.69 ± 1.62a | 17.43 ± 1.63a | 20.30 ± 2.72a | 40.36 ± 1.58b | −11.48% | 3.09% | 104.98% |
| HDL-C (mg/dL) | 24.75 ± 2.15a | 31.89 ± 0.23b | 30.78 ± 1.47b | 19.89 ± 1.21c | 28.85% | 24.36% | −19.63% |
Results are expressed as the mean ± SD, n = 8. Values in the same row not sharing a common superscript (a, b, and c) differ significantly with each other at p < 0.05. Percentage change is calculated as 100 × [(value of treatment − value of sham)/value of sham].
Figure 4The cardioprotective effects of SH on cardiac LPO levels. The bars represent the mean ± SD (n = 8); bars with different letters are significantly different at p < 0.05.
The cardioprotective effects of SH on the activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GRx) in the heart tissues of experimental animals.
| Parameters | Treatment | Percentage change | |||||
|---|---|---|---|---|---|---|---|
| Sham | SH + sham | SH + ISO | ISO | SH + sham | SH + ISO | ISO | |
| SOD (units/mg of protein) | 1.71 ± 0.14a | 1.41 ± 0.00a | 0.92 ± 0.01ab | 0.02 ± 0.00b | −17.54% | −46.19% | −98.83% |
| GPx (nmol NADPH oxidized/min/mg of protein) | 3.18 ± 0.00a | 2.59 ± 0.73a | 2.31 ± 0.06a | 1.02 ± 0.10b | −18.55% | −27.36% | −67.92% |
| GRx (nmol NADPH oxidized/min/mg of protein) | 97.91 ± 1.71a | 99.79 ± 3.83a | 97.53 ± 0.00a | 81.69 ± 1.56b | 1.92% | −0.39% | −16.57% |
Results are expressed as the mean ± SD, n = 8. Values in the same row not sharing a common superscript (a and b) differ significantly with each other at p < 0.05. Percentage change is calculated as 100 × [(value of treatment − value of sham)/value of sham].
Figure 5The effects of SH pretreatment on histopathological changes in the heart tissues of experimental rats. (a) Sham group: normal control rat heart showing normal cardiac muscle fibers; (b) SH + sham group: SH pretreated rat heart showing normal muscle fibers without any pathological changes; (c) SH + ISO group: SH pretreated rat myocardial tissues experiencing ISO challenge showing hyperplastic muscle fibers and decreased degree of inflammatory cells; (d) ISO group: only ISO treated rat heart showing cardiac muscle fibers with muscle separation (red arrows), edematous intramuscular space (green arrows), and inflammatory cell infiltration (yellow arrows). Magnification: 40x.
Semiquantitative scoring of the architectural changes evidenced by histopathological examination of rat myocardial tissues.
| Parameters | Treatment | |||
|---|---|---|---|---|
| Sham | SH + sham | SH + ISO | ISO | |
| Membrane integrity | − | − | − | +++ |
| Separation of muscle fiber | − | − | − | +++ |
| Infiltration of inflammatory cells | − | − | ++ | +++ |
| Edematous intramuscular space | − | − | + | +++ |
Scoring was performed as follows: none (−), mild (+), moderate (++), and severe (+++).
Comparison on percentage change for similar biomarkers between SH and TH pretreatment.
| Parameters | Tualang honey treatment | Percentage change (%) | |||
|---|---|---|---|---|---|
| Sham | TH + ISO | ISO | TH | SH | |
| cTn I (ng/mL) | 0.06 ± 0.01 | 0.18 ± 0.05 | 0.69 ± 0.05 | 80.38 | 91.02 |
| CK-MB (U/L) | 94.44 ± 3.05 | 158.03 ± 7.59 | 242.39 ± 7.30 | 57.02 | 60.89 |
| LPO (nmol TBARS/mg of protein) | 9.25 ± 0.68 | 16.84 ± 1.06 | 22.42 ± 1.09 | 42.36 | 91.46 |
| SOD (units/mg of protein) | 1.46 ± 0.05 | 0.19 ± 0.02 | 0.16 ± 0.01 | 2.31 | 53.25 |
| GPx (nmol NADPH oxidized/min/mg of protein) | 2.86 ± 0.06 | 1.86 ± 0.20 | 1.07 ± 0.19 | 44.13 | 59.72 |
| TC | 45.55 ± 2.49 | 56.77 ± 3.70 | 76.52 ± 4.84 | 63.77 | 75.82 |
| TGs | 46.31 ± 3.68 | 53.37 ± 3.91 | 72.88 ± 3.28 | 73.41 | 99.75 |
Results are expressed as the mean ± SD, n = 10. Percentage of protection provided by each honey type is calculated as 100 × [(value of ISO group − value of honey + ISO group)/(value of ISO group − value of sham group)]. TH: Tualang honey and SH: Sundarban honey.